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IMPORTANCE Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are
rare, acute, life-threatening dermatologic disorders involving the skin andmucous
membranes. Research into these conditions is hampered by a lack of standardization of case
reporting and data collection.
OBJECTIVE To establish a standardized case report form to facilitate comparisons and
maintain data quality based on an international panel of SJS/TEN experts who performed a
Delphi consensus-building exercise.
EVIDENCE REVIEW The elements presented for committee scrutiny were adapted from
previous case report forms and from PubMed literature searches of highly citedmanuscripts
pertaining to SJS/TEN. The expert opinions and experience of themembers of the consensus
group were included in the discussion.
FINDINGS Overall, 21 out of 29 experts who were invited to participate in the online Delphi
exercise agreed to participate. Surveys at each stage were administered via an online survery
software tool. For the first 2 Delphi rounds, results were analyzed using the Interpercentile
Range Adjusted for Symmetry method and statements that passed consensus formulated a
new case report form. For the third Delphi round, the case report formwas presented to the
committee, who agreed that it was “appropriate and useful” for documenting cases of
SJS/TEN, making it more reliable and valuable for future research endeavors.
CONCLUSIONS AND RELEVANCE With the consensus of international experts, a case report
form for SJS/TEN has been created to help standardize the collection of patient information
in future studies and the documentation of individual cases.
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T oxic epidermal necrolysis (TEN) and Stevens-Johnson Syn-drome (SJS) are acute life-threatening dermatologic disor-ders that involve the skin and mucous membranes and
arise mostly from severe adverse drug reactions. These conditions
are characterized by epidermal necrosis, leading to erosions of the
mucous membranes, widespread detachment of the epidermis,
and severe constitutional symptoms.1,2 The incidence of TEN is
estimated at 0.4 to 1.2 cases per million person-years, while SJS is
estimated at 1.0 to 6.0 cases per million person-years.3 Although
rare, these disorders are associated with high morbidity and mor-
tality even in previously healthy patients.4
SomeviewTENandSJSasvariantsof the samedisease thatdif-
fer in theextentof skindetachment,withSJSdefinedashaving less
than 10% body surface area involvement and TEN defined as in-
volvement of more than 30% of body surface area. For the pur-
poses of this discussion, the term “SJS/TEN” refers to the spec-
trum of epidermal necrolysis disorders.
More than 100 drugs have been implicated in causing
SJS/TEN.5-8While drugs are important causes of both SJS/TEN, in-
fectious etiologies (or a combination of infections and drugs) and
malignancy-related causes have also been implicated in SJS.9,10 In
fact, SJS is idiopathic in 25% to50%of cases.11 Genetic susceptibil-
ity also plays a role in SJS/TEN, as evidenced by the identification
of specific drug-associated human leukocyte antigen (HLA)
alleles.12-14 In addition, the pathophysiology of SJS/TEN is not well
established, but the release of granulysin by cytotoxic lympho-
cytes and natural killer cells is thought to play a central role.12,15 Re-
cent studies linking HLA to drug-induced SJS/TEN have also high-
lightedthe importanceofTcells.16-22Theseseminaldiscoverieswere
madepossiblebycarefullydocumentedcasesofTEN.Evenso, there
is no universally accepted standardized case report form for har-
monized international reporting of TEN, the creation of which was
one goal of this National Institutes of Health (NIH) SJS/TEN work-
ing group.
General guidelines for the diagnosis of SJS/TEN are typically
based on the morphology and extent of the lesions in the setting
of antecedent drug exposure or illness. Scoring systems have been
used to assess the mortality risk in these patients, including the
severity-of-illness score of toxic epidermal necrolysis (SCORTEN)
scale.23 However, due in part to the rarity of the condition, diag-
nostic criteria have not yet been established, which contributes to
the challenge of performing high-quality retrospective studies on
these patients.
For these andother reasons, there is a paucity of valuable clini-
cal studies onSJS/TEN. In 2015, theNIHand theFoodandDrugAd-
ministration (FDA) organized aworkshopentitled “ResearchDirec-
tions in Genetically-Mediated Stevens-Johnson Syndrome/Toxic
Epidermal Necrolysis” (https://www.genome.gov/27560487) that
was attended by an international panel of SJS/TEN experts. To
advance the field, one of the immediate next steps identified was
comparing and harmonizing case report forms and phenotyping
forms. Uniform case report forms standardize the collection of
patient information in a clinical study, which play a significant role
in maintaining data quality. Similarly, high-quality standardized
information is necessary to interpret individual case reports.Herein
wepresent a validated case report formcreated from the results of
aDelphiexerciseperformedbyanNIHWorkingGroupofparticipants
from the 2014 NIH/FDAWorkshop.
Methods
Panel Selection
A panel of epidermal necrolysis experts (dermatologists, pharma-
cologists, and immunologists) from 16different institutes and7dif-
ferent countries was assembled for a Delphi exercise to establish a
standardizedSJS/TENcase report form. Twenty-nine expertswere
identified from the NIH/FDA workshop and received email invita-
tions toparticipate in theDelphi consensus-buildingexercise. Seven
individuals didnot respond, 1 declined, and the remaining21 agreed
to participate (Figure).
First Round
Participantswere asked to evaluate the level of appropriateness of
62 statements in relation to SJS/TEN using a scale of 1 (extremely
inappropriate) to 9 (extremely appropriate). The elements pre-
sentedwereadapted fromprevious case report formsandPubMed
literature searchesofhighly citedmanuscriptsonSJS/TEN.They in-
cluded informationaboutpathophysiology, risk factors, patienthis-
tory, signs and symptoms, diagnosis, treatment and outcome. Par-
ticipants had the option of selecting “N/A” (not applicable) if they
did not feel that they had the necessary expertise or background
knowledge to rank a particular statement.
Surveys were administered online via SurveyMonkey and
results were deidentified prior to releasing them to participants.
Participants could also submit comments to be incorporated into
subsequent Delphi rounds.
Statistics
Using the RAND/UCLA Appropriateness Method,24 each item was
evaluatedby the 1-to-9appropriateness rating scaleandby the level
of disagreement. Amedian appropriateness value of 1.0 to 3.4was
considered “inappropriate;” 3.5 to 6.9, “uncertain;” and 7.0 to 9.0,
“appropriate.” A disagreement index (DI) was calculated as de-
scribed in eAppendix 1 in the Supplement. ADI value greater than 1
indicated a lack of consensus among the participants in regards to
the appropriateness of the statement.
Second Round
In the second round, participants ranked new statements sug-
gestedbythepanelandrevisedversionsof thestatements that failed
the first round.
Figure. SJS/TENDelphi Exercise Participants
29 Experts in SJS/TEN were invited to participate in a Delphi
consensus-building exercise to establish a standardized
case report form
7 Declined 21 Agreed
Case report form was developed
after 3 rounds of the Delphi
consensus-building exercise
Overall, 29 international experts on Stevens-Johnson syndrome and toxic
epidermal necrolysis (SJS/TEN) were invited, and 21 agreed to participate.
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Third Round
Statements thatwereagreedupon (DI < 1) tobe “appropriate” (me-
dian rating,7.0) were used to develop a new set of case report
forms for SJS/TEN (eAppendix 2 in the Supplement). A final ver-
sionwas presented to the panel for rating the appropriateness and
usefulness of the newly proposed case report forms.
Results
Participant Responses
All 21 participants responded to the first Delphi questionnaire
(100% response rate), and 16 of 21 participated in the second (76%
response rate). The results of the first 2 rounds are presented in the
Table.
For the third Delphi round, a set of case report forms was cre-
ated using the approved statements and the panel “agreed”
(DI = 0.31) that the formswere “very appropriate/veryuseful” (me-
dian value, 7). The response rate for the final exercise was 71% (15
of 21 participants).
Case Report Form
After the first round of the Delphi exercise, the panel agreed on
the following items. First, SJS and TEN are a single disease with
common causes and mechanism and require epidermal detach-
ment for diagnosis. The key difference between the 2 is the
extent of epidermal detachment. Second, despite having similar
mucosal erosions, erythema multiforme major (EMM) and SJS are
2 distinct diseases with different patterns of cutaneous lesions.
Third, the most reliable method to classify EMM, SJS, and TEN is
based on the morphology and extent of epidermal detachment.
Finally, mucous membrane erosions are present in all patients
with SJS/TEN.
Clinical features such as morphology of the lesions, a positive
Nikolsky sign, and constitutional symptoms were deemed helpful
in the diagnosis of SJS/TEN. Calculating a SCORTEN was also
deemed helpful. There was agreement that all patients diagnosed
with SJS or TEN should receive urologic evaluation and inpatient
OB/GYN screening and outpatient follow-up for female patients. All
patients should also receive outpatient ophthalmology follow-up
and pulmonary follow-up if there is evidence of pulmonary
involvement.
The second round revealed agreements on the work-up, man-
agement, and prevention of SJS and TEN. In particular, prior to
starting allopurinol or carbamazepine in a patient of Chinese
descent or of other genetically at-risk populations, HLA-B*58:01
and HLA-B*15:02 testing should be considered, respectively. There
was strong agreement that while patients with TEN should be
managed in a specialized intensive care unit or burn unit, there is
insufficient evidence that any specific treatment aside from sup-
portive care is beneficial for patients with TEN.
Using the statements that the panelists “agreed”were “appro-
priate” in regards to SJS/TEN, a new case report form was devel-
oped. For the third and final Delphi round, the committee came to
an agreement that the proposed case report form was “appropri-
ate and useful” for documenting cases of SJS/TEN, making it more
reliable and valuable for future research endeavors.
Table. Disagreement Indices for Each Proposed Item
Item
Disagreement
Index
Items the panel agreed were “appropriate” for the diagnosis of TEN
SJS and TEN are a single disease with common causes and
mechanisms. The principal difference between SJS and TEN
is the extent of epidermal detachment, which is limited in
SJS and more widespread in TEN.
0.44
SJS and TEN are most frequently caused by drugs 0.09
SJS and TEN may be caused by infectious triggers. 0.37
SJS and TEN may be idiopathic in some cases. 0.16
Drugs discontinued more than 1 month prior to onset
of mucocutaneous physical findings are highly unlikely to
cause SJS and TEN.
0.13
Drugs administered longer than 8 weeks prior to the onset
of mucocutaneous physical findings are highly unlikely to
cause SJS and TEN.
0.65
SJS and TEN most often begin between 4 and 28 days after
culprit drug administration.
0.13
Drugs highly associated with SJS and TEN include
nevirapine, lamotrigine, carbamazepine, phenytoin,
phenobarbital, allopurinol, anti-infective sulfonamides,
oxicam-NSAIDs, and sulfasalazine.
<0.01
Valproic acid alone is not a major risk factor for the
development of SJS and TEN.
0.48
Sulfonamide-related diuretics and antidiabetics are not
major risk factors for the development of SJS and TEN
0.82
Acetaminophen (paracetamol) has a low associated risk for
the development of SJS and TEN.
0.16
β-blockers, ACE inhibitors, calcium channel blockers,
thiazide diuretics, furosemide, sulfonylurea antidiabetics,
insulin, and propionic acid NSAIDs are probably not
associated with SJS and TEN.
0.92
SCORTEN accurately predicts the risk of death in patients
with SJS and TEN.
0.22
It is helpful to calculate a SCORTEN within the first 3 days
of hospitalization.
0.16
It is helpful to use the ALDEN, an algorithm used to assess
drug causality, for all patients suspected of having SJS
or TEN.
0.16
It is essential to obtain detailed information on ethnicity in
all patients suspected of having SJS or TEN.
0.68
It is essential to take a medication history in all patients
suspected of having SJS and TEN.
<0.01
It is essential to take a medical history in all patients
suspected of having SJS and TEN.
<0.01
Patients with SJS or TEN caused by a drug have a better
prognosis the earlier the causative drug is withdrawn.
0.13
SJS and TEN are often heralded by fever, sore throat, cough,
and burning eyes for 1 to 3 days.
0.19
Patients with SJS and TEN frequently experience burning
pain of their skin at the start of disease.
0.24
Characterization of lesion morphology is helpful in the
diagnosis of EMM, SJS, and TEN.
0.13
The most reliable method to classify EM, SJS, and TEN is
based on lesion morphology and extent of epidermal
detachment.
0.13
Classification of SJS and TEN should be based on percent
of epidermal detachment alone.
0.79
Classification of SJS and TEN should be based on the nature
of discrete lesions and percent of epidermal detachment.
0.16
Documentation of body surface area of baseline skin
erythema is essential in all patients suspected of having
SJS and TEN.
0.19
A positive Nikolsky sign is helpful in the diagnosis of SJS
and TEN.
0.33
Obtaining baseline photographs of all patients suspected
of having SJS and TEN is essential.
0.65
Obtaining baseline photographs of all patients suspected
of having SJS and TEN is helpful but not essential.
0.29
(continued)
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Discussion
The goal of this Delphi exercise was to obtain a consensus of the
elements needed to be included in a SJS/TEN standardized case
report form. During each round, individuals were uniformly encour-
aged to give commentary on how to improve the statements or the
case report form. Importantly, minority opinions that did not make
the final result include adding a more detailed or complete HLA
analysis and soliciting a baseline psychological history. Expanding
the HLA analysis was decided against because of the low preva-
lence of other knownmutations.
Table. Disagreement Indices for Each Proposed Item (continued)
Item
Disagreement
Index
Typical target lesions are not present in SJS or TEN. 0.08
In the presence of epidermal detachment, atypical target
lesions and macules with or without blisters are not required
to diagnose TEN.
0.29
Mucous membrane erosions are present in all patients with
SJS and TEN.
0.98
The epithelium of the trachea, bronchi, or gastrointestinal
tract may be involved in SJS and TEN.
<0.01
Involvement of the trachea, bronchi, or gastrointestinal
tract in SJS and TEN increases morbidity.
0.13
Epidermal detachment is required for a diagnosis of TEN. 0.05
A skin biopsy is helpful, but not required, to establish a
diagnosis of SJS and TEN.
0.19
A skin biopsy for direct immunofluorescence is helpful, but
not essential, in the evaluation of SJS and TEN
0.79
Establishment of a diagnosis of SJS and TEN by a
dermatologist is helpful but not essential.
0.19
Regardless of presenting symptoms, all female patients
diagnosed with SJS or TEN should receive OB/GYN inpatient
screening and offered outpatient follow-up.
0.71
Regardless of presenting symptoms, all patients diagnosed
with SJS/TEN should receive ophthalmology inpatient
screening and offered outpatient follow-up.
0.05
It is helpful for patients diagnosed with SJS or TEN to
receive outpatient ophthalmology follow-up regardless
of the presence of ocular symptoms.
0.29
It is helpful for all patients diagnosed with SJS or TEN
to receive urologic evaluation.
0.67
It is helpful for all patients with SJS or TEN demonstrating
evidence of pulmonary involvement to receive outpatient
pulmonary follow-up.
0.29
Mucosal lesions of SJS and TEN can heal with scar formation
and adhesions.
0.13
Late ocular complications may develop in patients with
SJS and TEN whether or not severe initial eye involvement
is noted.
0.19
Restrictive lung disease may develop in patients with SJS
and TEN after initial acute pulmonary involvement.
0.13
Esophageal strictures or adhesions may develop in patients
with SJS and TEN after initial acute esophageal involvement.
0.29
Drugs administered 24 hours or less prior to the onset of
mucocutaneous physical findings are unlikely to cause TEN.
0.13
Slow titration of a drug does not decrease the risk of it
causing TEN.
0.32
Patients with TEN may experience pruritus of their skin
at the start of disease.
0.26
Skin lesions of TEN usually start to re-epithelialize within 14
days and may heal without scarring. Patients may develop
temporary postinflammatory hyperpigmentation.
0.19
In a patient with TEN, a Nikolsky sign may be elicited on
erythematous areas of skin but may not be reliably
elicited on normal appearing skin.
<0.01
It is essential to obtain an adverse drug reaction history
(both for patient and family) in all patients suspected
of having TEN.
0.13
In patients younger than 50 years, those who develop TEN
without a suspected drug should be tested for
mycoplasma pneumoniae.
0.63
Prior to starting allopurinol in a patient of Chinese descent,
HLA-B*58:01 testing should be considered.
0.13
Prior to starting carbamazepine in a patient of Chinese
descent, HLA-B*15:02 testing should be considered.
<0.01
When possible, patients with TEN should be managed in a
specialized intensive care unit or burn unit.
<0.01
There is no sufficient evidence to date that any specific
treatment aside from supportive care is beneficial for
patients with TEN.
<0.01
(continued)
Table. Disagreement Indices for Each Proposed Item (continued)
Item
Disagreement
Index
A complete blood count and comprehensive metabolic panel
is helpful in evaluating patients suspected of having TEN.
0.40
Items the panel agreed were “appropriate” for the diagnosis
of TEN
Examination of all mucosal sites is essential for patients
suspected of having TEN.
<0.01
Evaluation for associated symptoms is essential for patients
suspected of having TEN.
0.19
The severity and risk of development of SJS and TEN does
not change with a leadin or slow titration period of drugs
highly associated with SJS and TEN.
0.95
Each factor calculated in the SCORTEN carries equal
prognostic weight.
0.65
It is helpful but not essential to obtain detailed information
on ethnicity in all patients suspected of having SJS or TEN.
0.52
Patients with SJS and TEN frequently experience pruritus
of their skin at the start of disease.
0.97
Establishment of a diagnosis of SJS and TEN by a
dermatologist is essential.
0.37
The presence of lymphadenopathy is helpful in evaluating a
patient with TEN.
0.65
Assessing for viral reactivation (eg, herpes simplex virus) is
helpful in evaluating a patient with TEN.
0.53
Items the panel agreed were “inappropriate” for the diagnosis of TEN
SJS and TEN are exclusively caused by drugs 0.75
A skin biopsy is required to establish a diagnosis of SJS
and TEN.
0.42
A skin biopsy for direct immunofluorescence is essential
in the evaluation of SJS and TEN.
0.72
Items the panel disagreed on for the diagnosis of TEN
EMM, but not SJS/TEN, can be caused by infectious triggers
such as mycoplasma pneumoniae and Herpes simplex.
1.04
Drugs administered for less than 2 days prior to the onset of
mucocutaneous physical findings are highly unlikely to cause
SJS and TEN.
1.27
A Nikolsky sign may be elicited on erythematous areas of
skin, but usually not on normal-appearing skin, in patients
with SJS and TEN.
1.70
There is no correlation between the extent of epidermal
detachment and mucosal membrane erosion severity in SJS
and TEN.
1.46
Skin lesions of SJS and TEN usually heal rapidly without scar
formation.
1.04
Factors calculated in the SCORTEN do not carry equal
prognostic weight.
1.01
Abbreviations: ACE, angiotensin-converting-enzyme; EM, erythema
multiforme; EMM, erythemamultiformemajor; NSAID, nonsteroidal
anti-inflammatory drug; OB/GYN, obstetrics and gynecology;
SCORTEN, severity-of-illness score for toxic epidermal necrolysis;
SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
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Wehave includedvarious toolswithin thecase report formsuch
as the SCORTEN. We have not included a specific causality assess-
ment toolbecausemanydifferent tools areavailable, butnonehave
been shown to be superior. As part of this NIHworking group, a fu-
ture endeavor is to compare drug causality assessment tools, such
as the ALDEN (algorithm of drug causality for epidermal necroly-
sis) and Naranjo.25 Regardless of which tool is used, it is important
todocumentwhocompleted the causality assessmentbecause the
experience of the user can be a critical determinant of reliability.
Conclusions
Wehavegenerated,with the consensusof experts fromaround the
world, a case report form that is the first of its kind thatwe knowof
for SJS/TEN.Wearehopeful that itwill help in standardizing thecol-
lection of patient information in future studies and in the reporting
of individual cases ofmarketed drugs, leading to improved charac-
terization andmanagement of SJS/TEN.
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